Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios A Pappas

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
The Journal of Rheumatology|October 16, 2021
Dr. Kremer et al replyJoel M Kremer, George Reed, Dimitrios A Pappas, et al.
Rheumatology and Therapy|October 18, 2016
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona RegistryDimitrios A Pappas, Ani John, Jeffrey R Curtis, et al.
Arthritis Research & Therapy|April 29, 2017
Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritisGeorge W Reed, David H Collier, Andrew S Koenig, et al.
Rheumatology (Oxford, England)|May 30, 2023
Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologicsNozima Aripova, Joel M Kremer, Dimitrios A Pappas, et al.
Rheumatology and Therapy|October 31, 2023
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational StudyAnisha B Dua, Kerri Ford, Stefano Fiore, et al.
Rheumatology and Therapy|May 28, 2021
Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RALeslie R Harrold, Joshua Bryson, Thomas Lehman, et al.
Annals of the Rheumatic Diseases|May 30, 2013
Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung diseaseJon T Giles, Sonye K Danoff, Jeremy Sokolove, et al.
Annals of the Rheumatic Diseases|October 5, 2013
A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis riskAnnie Yarwood, Buhm Han, Soumya Raychaudhuri, et al.
Rheumatology (Oxford, England)|November 8, 2021
Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometryMichail K Alevizos, Sonye K Danoff, Dimitrios A Pappas, et al.
Annals of the Rheumatic Diseases|November 12, 2020
Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng <i>et al</i>Dimitrios A Pappas, Gregory St John, Carol J Etzel, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
The Journal of Rheumatology|October 16, 2021
Dr. Kremer et al replyJoel M Kremer, George Reed, Dimitrios A Pappas, et al.
Rheumatology and Therapy|October 18, 2016
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona RegistryDimitrios A Pappas, Ani John, Jeffrey R Curtis, et al.
Arthritis Research & Therapy|April 29, 2017
Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritisGeorge W Reed, David H Collier, Andrew S Koenig, et al.
Rheumatology (Oxford, England)|May 30, 2023
Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologicsNozima Aripova, Joel M Kremer, Dimitrios A Pappas, et al.
Rheumatology and Therapy|October 31, 2023
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational StudyAnisha B Dua, Kerri Ford, Stefano Fiore, et al.
Rheumatology and Therapy|May 28, 2021
Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RALeslie R Harrold, Joshua Bryson, Thomas Lehman, et al.
Annals of the Rheumatic Diseases|May 30, 2013
Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung diseaseJon T Giles, Sonye K Danoff, Jeremy Sokolove, et al.
Annals of the Rheumatic Diseases|October 5, 2013
A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis riskAnnie Yarwood, Buhm Han, Soumya Raychaudhuri, et al.
Rheumatology (Oxford, England)|November 8, 2021
Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometryMichail K Alevizos, Sonye K Danoff, Dimitrios A Pappas, et al.
Annals of the Rheumatic Diseases|November 12, 2020
Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng <i>et al</i>Dimitrios A Pappas, Gregory St John, Carol J Etzel, et al.
Pageof 8